BioSpace News Archive

FDA

Hikma’s Advair Generic Gets Further Delayed

Hikma Pharmaceuticals generic version of Advair has hit a stumbling block with the FDA.

March 12, 2018
·
2 min read
·
Mark Terry
Drug Development

Sarepta to Seek FDA Approval for Second DMD Treatment

After a hard-fought battle to win the green light for Exondys 51 from the U.S. Food and Drug Administration, Sarepta Therapeutics is planning on seeking approval of a second treatment for Duchenne muscular dystrophy (DMD).

March 12, 2018
·
3 min read
·
Alex Keown
Drug Development

Merrimack Pharmaceuticals Expands Phase II Lung Cancer Study

Merrimack Pharmaceuticals announced it is expanding enrollment in a Phase II lung cancer study.

March 12, 2018
·
2 min read
·
Alex Keown
Pharm Country

Sanofi and Regeneron Slash Cost of New Cholesterol Drug Praluent

Sanofi and Regeneron have cut deals to dramatically reduce the price of their new cholesterol drug Praluent.

March 12, 2018
·
3 min read
·
Mark Terry
Business

Immutep Strikes Deal with Merck to Pair Product With Keytruda in Phase II Trial

Immutep Limited announced it will pair its lead immunotherapy product with Merck’s blockbuster PD-1 inhibitor Keytruda to treat three solid tumor types in a single trial.

March 12, 2018
·
2 min read
·
Alex Keown
Drug Development

Realm Therapeutics Flunks PhII Trial for Conjunctivitis Drug

Realm Therapeutics announced today that its PR013, failed to show efficacy in its Phase II trial for allergic conjunctivitis.

March 12, 2018
·
2 min read
·
Mark Terry
Drug Development

Biogen Buys Pfizer’s PhII-ready Schizophrenia Asset

Biogen is buying Pfizer’s PF-04958242, a first-in-class, Phase IIb-ready drug to treat several neurological and psychiatric diseases, including schizophrenia.

March 12, 2018
·
3 min read
·
Mark Terry
Business

Gilead’s Chief Scientific Officer Steps Down

After serving nearly 30 years with the company Norbert Bischofberger is stepping down from his role as head of research and development and chief scientific officer of Gilead Sciences.

March 12, 2018
·
2 min read
·
Alex Keown
Career Advice

Why do we hate writing cover letters?

It’s no surprise. Job seekers hate writing cover letters. In fact, it’s arguably the most dreaded step in the job application process. But why?

March 12, 2018
·
7 min read
Deals

Anti-Obesity Drugmaker Orexigen Therapeutics Files for Bankruptcy

Shares of weight-loss drugmaker Orexigen Therapeutics are in free-fall this morning after the company announced it filed for bankruptcy.

March 12, 2018
·
2 min read
·
Alex Keown